Although a number of medical treatment advances for diabetic retinopathy (DR) and diabetic macular edema (DME) have occurred in recent years—predominantly through the introduction of the anti-vascular endothelial growth factor (VEGF) agen
Michelle Dalton, ELS
This year’s Retina Subspecialty Day at the American Academy of Ophthalmology meeting included a session devoted to diabetes—most of which highlighted study data from the Diabetic Retinopathy Clinical Research Network (DRCR.net).
November has been declared by Prevent Blindness as Diabetic Eye Disease Awareness Month to educate the public on the effects of diabetes on vision, risk factors and treatment options.
The Centers for Disease Control estimates that more than 84 million U.S. adults, or 40% of the U.S. adult population, is prediabetic.
Research finds limited publications and dearth of information about side effects
Findings from the PERMEATE study used novel diagnostics to quantify response to intravitreal injections
Alzheimer’s disease leads to severe cognitive dysfunction and eventual death; by 2050 it is expected to affect more than 115 million people worldwide. From time of diagnosis until death the average survival time is just under 5 years.
When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion.
Using a specific anti-vascular endothelial growth factor (VEGF) drug in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) can result i